Jaguar Health, Inc. (NASDAQ:JAGX) | Finanzwire

Basculer en Français

10051	Companies
205079	Keywords
135319	Articles
108728	Press releases

Home
Companies
Jaguar Health, Inc.

BRIEF

published on 01/12/2026 at 15:05, 2 months 6 days ago

Jaguar Health Secures U.S. License Deal with Future Pak for Crofelemer

Crofelemer Jaguar Health Future Pak U.S. License Agreement Rare-disease Pipeline
PRESS RELEASE

published on 01/12/2026 at 15:00, 2 months 6 days ago

Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million
Jaguar Health, Inc. enters U.S. licensing agreement with Future Pak, LLC for exclusive marketing rights of Mytesi® and Canalevia®-CA1, securing $18M upfront payment and potential $20M in milestone payments

Licensing Agreement Jaguar Health Canalevia-CA1 Mytesi Future Pak
BRIEF

published on 01/06/2026 at 15:05, 2 months 12 days ago

Jaguar Health's Crofelemer Shows Promise in Intestinal Failure Treatment

Crofelemer Jaguar Health Intestinal Failure Parenteral Support Pediatric Study
PRESS RELEASE

published on 01/06/2026 at 15:00, 2 months 12 days ago

Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication
Jaguar Health announced groundbreaking results from ongoing proof-of-concept study of crofelemer in pediatric patients with intestinal failure, showing significant reduction of parenteral support (PS) and potential to save lives

Crofelemer Jaguar Health Pediatric Patients Intestinal Failure Parenteral Support
BRIEF

published on 01/02/2026 at 15:05, 2 months 16 days ago

Jaguar Health Secures FDA Grant for Canalevia-CA1 Studies

Veterinary Medicine Jaguar Health Canalevia-CA1 Dog Diarrhea Treatment FDA Grant
PRESS RELEASE

published on 01/02/2026 at 15:00, 2 months 16 days ago

Jaguar Health Awarded $240,000 FDA Grant in Support of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Jaguar Health, Inc. receives $240,000 grant from FDA for Canalevia-CA1 study on chemotherapy-induced diarrhea in dogs. Focus on CID treatment effectiveness

Jaguar Health Canalevia-CA1 Chemotherapy-induced Diarrhea Grant Dogs
BRIEF

published on 12/15/2025 at 15:05, 3 months 3 days ago

Jaguar Health Submits Abstract for Crofelemer Trial in SBS-IF Patients

Short Bowel Syndrome Jaguar Health Orphan Drug Crofelemer Trial Intestinal Failure
PRESS RELEASE

published on 12/15/2025 at 15:00, 3 months 3 days ago

Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
Jaguar Health announces submission of abstract detailing preliminary findings from clinical trial on a novel oral liquid formulation of crofelemer for SBS-IF patients, supporting the focus on reducing PS needs in intestinal failure patients

Crofelemer Jaguar Health Clinical Trial SBS-IF Intestinal Failure
BRIEF

published on 12/10/2025 at 15:05, 3 months 8 days ago

FDA Extends Conditional Approval for Jaguar Health's Canalevia-CA1

FDA Approval Veterinary Medicine Jaguar Health Canalevia-CA1 Chemotherapy In Dogs
PRESS RELEASE

published on 12/10/2025 at 15:00, 3 months 8 days ago

FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs
Jaguar Health, Inc. (NASDAQ:JAGX) receives FDA renewal for Canalevia-CA1, a prescription drug for chemotherapy-induced diarrhea (CID) in dogs, with conditional approval extended until December 2026

Veterinary Medicine Jaguar Health Canalevia-CA1 Chemotherapy-induced Diarrhea FDA Renewal

Accesswire

Published on 03/18/2026 at 21:00, 2 hours 25 minutes ago

PLDT's Smart Selects Amdocs to Transform Retail Operations with AI-Powered Store Genie
Published on 03/18/2026 at 19:05, 4 hours 20 minutes ago

Deposit Modeling at Thor Shows that the Proven Thor Epithermal Deposit is Flanked on Both Sides by a Much Larger Deposit
Published on 03/18/2026 at 18:10, 5 hours 15 minutes ago

Silver X Mining Closes C$69M Brokered Private Placement of Secured Convertible Debentures
Published on 03/18/2026 at 14:30, 8 hours 55 minutes ago

Ground Geophysics Underway at Murphy Lake, 5 km From Isoenergy's Hurricane Deposit, Athabasca Basin
Published on 03/18/2026 at 14:15, 9 hours 10 minutes ago

Apex Provides Phase I Drilling Update at the Rift Rare Earth Project in Nebraska, U.S.A.

View all ACCESSWIRE

EQS Group

Published on 03/18/2026 at 22:00, 1 hour 25 minutes ago

aap successfully completes MDR certification: All existing products approved according to MDR – market access in the EU and CE-relevant markets secured in the long term
Published on 03/18/2026 at 18:53, 4 hours 32 minutes ago

EQS-Adhoc: Formycon AG postpones the publication of its audited annual and consolidated financial statements for 2025
Published on 03/18/2026 at 18:37, 4 hours 48 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 03/18/2026 at 18:27, 4 hours 58 minutes ago

POS-Transaction in Own Shares
Published on 03/18/2026 at 18:15, 5 hours 9 minutes ago

Northern Data Group releases audited FY 2025 Financial Results

Les Echos

Published on 03/18/2026 at 19:41, 3 hours 44 minutes ago

Covivio - Conditions of availability of the 2025 Universal Registration Document
Published on 03/18/2026 at 18:00, 5 hours 25 minutes ago

Deezer achieves profitability in FY25 as strategy delivers tangible results
Published on 03/18/2026 at 17:45, 5 hours 40 minutes ago

Infotel : 2025 full-year results. Launch of a new Infotel 2030 strategic plan. Revenue target of €500 million by 2030.
Published on 03/18/2026 at 17:40, 5 hours 45 minutes ago

260318 BENETEAU Presentation FY 2025
Published on 03/18/2026 at 17:40, 5 hours 45 minutes ago

260318 BENETEAU FY 2025 Results

View all LES ECHOS COMFI WIRE